Agonistic autoantibodies to the β2-adrenergic receptor involved in the pathogenesis of open-angle glaucoma by Jünemann, A. et al.
February 2018 | Volume 9 | Article 1451
Original research
published: 12 February 2018
doi: 10.3389/fimmu.2018.00145
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Robert Weissert, 
University of Regensburg, Germany
Reviewed by: 
Jennifer Maynard, 
University of Texas at Austin, 
United States  
Reinhild Klein, 
Universität Tübingen, Germany
*Correspondence:
Bettina Hohberger  
bettina.hohberger@uk-erlangen.de
†These authors have contributed 
equally to this work.
Specialty section: 
This article was submitted to Multiple 
Sclerosis and Neuroimmunology, 
a section of the journal 
Frontiers in Immunology
Received: 24 August 2017
Accepted: 17 January 2018
Published: 12 February 2018
Citation: 
Jünemann A, Hohberger B, Rech J, 
Sheriff A, Fu Q, Schlötzer-
Schrehardt U, Voll RE, Bartel S, 
Kalbacher H, Hoebeke J, Rejdak R, 
Horn F, Wallukat G, Kunze R and 
Herrmann M (2018) Agonistic 
Autoantibodies to the β2- 
Adrenergic Receptor Involved 
in the Pathogenesis of 
Open-Angle Glaucoma. 
Front. Immunol. 9:145. 
doi: 10.3389/fimmu.2018.00145
agonistic autoantibodies to the  
β2-adrenergic receptor involved  
in the Pathogenesis of Open- 
angle glaucoma
Anselm Jünemann1†, Bettina Hohberger 2*†, Jürgen Rech3, Ahmed Sheriff 3, Qin Fu4,5, 
Ursula Schlötzer-Schrehardt2, Reinhard Edmund Voll6, Sabine Bartel5, Hubert Kalbacher7, 
Johan Hoebeke8, Robert Rejdak9, Folkert Horn2, Gerd Wallukat5†, Rudolf Kunze10† and 
Martin Herrmann3†
1 Department of Ophthalmology, University of Rostock, Rostock, Germany, 2 Department of Ophthalmology, Friedrich-
Alexander-University of Erlangen-Nürnberg, Erlangen, Germany, 3 Department of Internal Medicine III, Institute of Clinical 
Immunology and Rheumatology, University of Erlangen-Nürnberg, Erlangen, Germany, 4 Department of Pharmacology, Tongji 
Medical College, Huazhong University of Science and Technology, Wuhan, China, 5 Max Delbrück Center for Molecular 
Medicine, Berlin, Germany, 6 IZKF Research Group 2, Nikolaus-Fiebiger-Center of Molecular Medicine, University of Erlangen-
Nürnberg, Erlangen, Germany, 7 IFIB - Institute of Biochemistry, University of Tübingen, Tübingen, Germany, 8 C.N.R.S. UPR 
9021 «Chimie et Immunologie Thérapeutiques», Strasbourg, France, 9 Department of General Ophthalmology, Medical 
University of Lublin, Lublin, Poland, 10 Science Office, Berlin-Buch, Campus Max Delbrück Center for Molecular Medicine, 
Berlin, Germany
Glaucoma is a frequent ocular disease that may lead to blindness. Primary open-angle 
glaucoma (POAG) and ocular hypertension (OHT) are common diseases with increased 
intraocular pressure (IOP), which are mainly responsible for these disorders. Their patho-
genesis is widely unknown. We screened the sera of patients with POAG and OHT for 
the prevalence of autoantibodies (AAb) against G protein-coupled receptors (GPCRs) in 
comparison to controls. Employing frequency modulation of spontaneously contracting 
neonatal rat cardiomyocytes in vitro, agonistic GPCR AAb were to be detected in roughly 
75% of the patients with POAG and OHT, however, not in controls. Using inhibitory 
peptides the AAb’ target was identified as β2 adrenergic receptor (β2AR). The AAb 
interact with the second extracellular loop of β2AR. The peptides 181–187 and 186–192 
were identified as binding sites of the AAb within the extracellular loop II. The binding 
of the AAb to β2ARs was verified by surface-plasmon-resonance analysis. The isotype 
of the AAb was (immunoglobulin) IgG3. In an additional pilot principal-of-proof study, 
including four patients with POAG, the removal of the AAb against the β2AR and other 
immunoglobulins G by immunoadsorption resulted in a transient reduction of IOP. These 
findings might indicate a possible role of agonistic AAb directed against β2ARs in the 
dynamics of aqueous humor and might support a contribution of adaptive autoimmunity 
in the etiopathogenesis of POAG and OHT.
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inTrODUcTiOn
Glaucoma is one of the leading causes of blindness in the world. Over 67 million people are affected 
by glaucoma (1, 2). Elevated intraocular pressure (IOP) is the major risk factor for glaucoma. 
Primary open-angle glaucoma (POAG) is now defined as a progressive disease of retinal ganglion 
cells characterized by structural change in the optic disk and by typical, slowly progressive loss of 
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function. The most common form of the group of glaucomatous 
diseases is POAG with about 80%. Ocular hypertension (OHT) is 
characterized by elevated IOP without optic nerve degeneration. 
One to 2% of patients with OHT per year convert to POAG.
The pathogenesis of the optic nerve damage in POAG is 
complex and associated with increased IOP, neurotoxicity and 
apoptosis (3, 4), changes of the extracellular matrix (5, 6), activa-
tion of glia cells (7), an interrupted transport of neutrophins (8), 
oxidative stress (9, 10), and hypoxia due to ocular and systemic 
vascular dysregulation (9). There are also reports of glaucoma-
associated degenerative processes of the central visual pathways 
in the brain (11). Thus, new targets for therapeutic intervention, 
such as improving ocular blood flow and direct neuroprotection 
of retinal ganglion cells, are under investigation.
Since elevated IOP is the primary risk factor for the develop-
ment and progression of glaucoma, the lowering of the IOP is the 
primary goal of all treatment strategies (12). Many studies have 
shown that IOP reduction can slow the progression of glaucoma 
(13–17) and delay or even prevent the onset of retinal ganglion 
cell loss. Lowering the IOP by 1  mmHg prevents progressive 
visual field loss by 10% (18). Conservative [e.g., β2-adrenergic 
receptor (β2AR) blocker] and surgical therapeutic options are 
offered to achieve IOP lowering. The β2AR blocker Timolol 
reduces the IOP in humans (19) by suppressing the rate of aque-
ous humor formation (20, 21) by 30–50% (20–26). The relative 
potency of the β2-adrenergic blocker Timolol is higher than that 
of the β1-adrenergic receptor blocker Betaxolol (27), indicating 
the prominent role of β2ARs in the formation of aqueous humor 
and/or regulation of its flow.
Trabecular meshwork and ciliary body express β2ARs (28, 29), 
regulating the aqueous humor system in the eye and consequently 
influencing IOP. Thus, β2AR plays a key role in the regulation 
of both aqueous humor production and outflow. In addition, 
β2AR is also expressed in human optic nerve and in microvessels 
(30, 31). β2ARs are members of the G protein-coupled receptors 
(GPCR) family, comprised of more than 600 genes (32, 33). 
They have seven membrane spanning domains, three intra- and 
extracellular loops, an extracellular N-terminus, and an intracel-
lular C-terminal tail. Most of the GPCR form homodimers upon 
ligand activation. It has been shown that functional autoantibod-
ies (AAbs), directed against GPCR, are associated with various 
human diseases. The first AAb against a GPCR was described for 
the β2AR in patients with allergic asthma in 1980 (34). Several 
groups identified agonistic AAb against the β1-adrenergic recep-
tor in Chagas’ disease (35, 36), dilated cardiomyopathy (37–39), 
ischemic cardiomyopathy (40), and myocarditis (41). β2- and 
α1-AAb were seen in Alzheimer’s and vascular dementia (42). 
β1-, β2-, and α1-AAb were shown to be increased in patients with 
preeclampsia (43). α1-AAb were also detected in primary and 
malignant hypertension (44).
We hypothesize that AAb against GPCR might be involved 
in the pathogenesis of glaucomatous disease by influencing the 
dynamics of aqueous humor.
To study the hypothesis that circulating immunoglobulins 
of patients with glaucoma activate GPCRs, isolated rat cardio-
myocytes were employed as target cell. Frequency modulation of 
spontaneously beating neonatal cardiomyocytes is highly efficient 
to investigate such targets (1–3, 37, 45). The rat cardiomyocytes 
contain a spectrum of relevant GPCRs, e.g., β1-, β2-, α-ARs, and 
Angiotensin-1 receptor, which display a high homology to their 
corresponding human receptors. The homology of the amino 
acids between the human and the rat second extracellular loop is 
88%; however, the homology in the estimated binding site of the 
AAbs in this extracellular loop is 100%. The cells were exposed 
to IgG prepared from controls or patients with glaucoma and 
OHT. To verify the specificity of the effects, the heart cells were 
treated with receptor-specific agonists in the presence or absence 
of receptor-specific antagonists and compared with the AAb-
mediated responses. In screening studies using respective agonists 
and blocking agents an interaction of the glaucoma-associated 
IgG with the β1AR, α-AR, or with AT1-receptor system has been 
excluded (not shown). Based on these findings, the potential 
importance of β2AR-directed antibodies associated with glau-
coma was analyzed in more detail. These findings were the basis 
for the following experiments. Investigations of the target loop as 
well as the target epitope of the GPCR and the IgG isotype of the 
AAb were added. Surface plasmon resonance analysis confirmed 
the receptor specificity of the agonistic β2AR AAb.
In order to draw a bow between the molecular findings 
and clinical data, correlation analyses of the patients’ clinical 
parameter with the β2AR AAb were done. Finally, a pilot proof-
of-principal study was performed in four glaucoma patients using 
an extracorporal immunoadsorption (IA) for removal of AABs 
against β2AR and other immunoglobulins G in order to monitor 
a potentially transient or permanent change of IOP.
MaTerials anD MeThODs
Patients
Patients with POAG and patients with OHT were recruited from 
the Department of Ophthalmology of the University of Erlangen-
Nürnberg (Friedrich-Alexander-Universität Erlangen-Nürnberg 
(FAU)). The control groups were from the Max Delbrück Centre 
of Molecular Medicine Berlin (MDC) and from the University of 
Erlangen-Nürnberg [normal healthy donors (NHD) and cataract 
patients].
All controls and patients were thoroughly examined by slit 
lamp inspection, applanation tonometry, funduscopy, gonios-
copy, perimetry, and papillometry. In addition, a 24 h IOP curve 
was measured in all glaucoma patients (6 determinations: 7:00 
a.m., 12:00 a.m., 5:00 p.m., 9:00 p.m., 12:00 p.m., and 7:00 a.m.). 
Papillometric evaluations of the patients were based on 15-color 
photographs and subsequent planimetry (Zeiss Morphomat 
30) of the area of the optic disk and the neuroretinal rim area 
(46). Criteria for all glaucoma diagnoses were an open anterior 
chamber angle and glaucomatous changes of the optic nerve head 
including an unusually small neuroretinal rim area in relation 
to the optic disk size and higher vertical cup-to-disk ratios than 
horizontal ratios (45). All subjects underwent visual field testing 
with standard white-on-white perimetry using a computerized 
static projection perimeter (Octopus 500, Interzeag, Schlieren, 
Switzerland; program G1, 3 phases). Subjects with more than 
12% false-positive or false-negative responses were not included 
Table 4 | General diseases of patients with primary open-angle glaucoma 
(POAG) and ocular hypertension (OHT).
POag OhT
Diabetes 9 (23%) 0
Arterial hypertension 20 (51%) 3
Heart insufficiency 2 (5%) 0
Coronary heart disease 5 (13%) 0
Myocardial infarction 2 (5%) 0
Cardiac arrhythmia 3 (8%) 0
Stroke 3 (8%) 0
Immunological disease 4 (10%) 0
Rheumatoid arthritis 1
Muscle rheumatism 1
Psoriasis 1
Raynaud’s phenomenon 1
Thyroid disease 7 (18%) 0
Table 3 | Glaucoma therapy of patients with primary open-angle glaucoma 
(POAG) and ocular hypertension (OHT).
Therapy POag (n) OhT (n)
Antiglaucomatous medication 10 7
Glaucoma surgery without medication 6 0
Glaucoma surgery with medication 23 0
Number of antiglaucomatous medication
0 3 2
1 13 4
2 5 3
3 11 0
4 4 0
Antiglaucomatous medication
Betablockers 23 1
Prostaglandins 21 7
CAI 19 1
A2-agonists 7 1
Pilocarpine 4 0
CAI, carboanhydrase inhibitor.
Table 2 | Clinical characteristics of control group.
cataract patients normal healthy donors
Number 8 9
Age (years) 71.0 ± 10.7 (55–83) 44.6 ± 15.4 (22–65)
Gender 3 m (37%), 5 f (63%) 1 m (11%), 8 f (89%)
IOPact (mmHg) OD 13.3 ± 2.5 (10–17)
IOPact (mmHg) OS 13.6 ± 3.4 (10–21)
Visual acuity OD 0.47 ± 0.3 (0.002–1.0)
Visual acuity OS 0.59 ± 0.3 (0.002–1.0)
IOPact, actual intraocular pressure; OD = right eye. OS, left eye; m, male, f, female.
Table 1 | Clinical characteristics of patients with primary open-angle glaucoma 
(POAG) and ocular hypertension (OHT).
POag OhT
Number 39 9
Age (years) 71.18 ± 8.8 (48–86) 51.0 ± 7.7 (42–68)
Gender 12 m (31%), 17 f (69%) 5 m (56%), 4 f (44%)
Glaucoma history (years) 15.2 ± 11.1 (1–39) 6.8 ± 3.9 (3–14)
IOPmax (mmHg) OD 34,2 ± 12,7 (20–67) 28.7 ± 3.7 (23–35)
IOPmax (mmHg) OS 33.0 ± 12.2 (19–67) 26.9 ± 4.1 (22–35)
IOPact (mmHg) OD 17.8 ± 6.8 (10–38) 15.7 ± 3.9 (9–21)
IOPact (mmHg) OS 17.5 ± 5.7 (9–42) 17.4 ± 3.7 (13–22)
MD (dB) OD 10.8 ± 7.9 (−4.3 to 25.0) −0.13 ± 0.96 (−1.5 to 1.5)
MD (dB) OS 11.9 ± 7.9 (−0.7 to 28.6) 0.25 ± 1.1 (−1.4 to 1.8)
CLV (dB2) OD 42.2 ± 32.1 (4.0–112.7) 3.15 ± 1.42 (1.5–5.8)
CLV (dB2) OS 40.7 ± 26.1 (1.7–124.0) 3.1 ± 1.7 (1.8–6.8)
Visual acuity OD 0.59 ± 0.3 (0.002–1.2) 1.0 ± 0.1 (1.0–1.2)
Visual acuity OS 0.59 ± 0.3 (0.004–1.0) 1.1 ± 0.1 (0.8–1.2)
Values are given as mean ± SD (range).
IOPmax, maximal intraocular pressure; IOPact, actual intraocular pressure; MD, mean 
defect; CLV, corrected loss variance; OD, right eye; OS, left eye; m, male; f, female.
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in this study. A glaucomatous visual field was defined as an 
white-on-white visual field with (a) at least three adjacent test 
points having a deviation of equal to or greater than 5 dB and 
with one test point with a deviation greater than 10 dB lower than 
normal, (b) at least two adjacent test points with a deviation equal 
to or greater than 10  dB, (c) at least three adjacent test points 
with a deviation equal to or greater than 5 dB abutting the nasal 
horizontal meridian, or (d) a mean visual field defect of more 
than 2.6 dB. Exclusion criteria were all eye diseases other than 
glaucoma, OHT or cataract, respectively. The clinical character-
istics of controls (cataract and NHD) and patients can be found 
in Tables 1 and 2. For the patients, antiglaucomatous therapy and 
general diseases are given in Tables 3 and 4.
The study followed the tenets of the declaration of Helsinki 
for research. Written informed consent to use serum samples for 
research purposes was obtained from each participants of the 
study. The institutional review board of the University Hospital 
Erlangen approved the protocols.
POAG Patients
The patients of the glaucoma group were referred by ophthal-
mologists for further diagnosis and follow-up of glaucoma. The 
POAG group included 39 patients with POAG, characterized by 
IOP measurements higher than 21  mmHg. All POAG patients 
had glaucomatous optic disk damage and pathological cumulative 
perimetric defect curves, i.e., local and/or diffuse visual field loss 
in white-on-white perimetry.
OHT Patients
The OHT group included 9 patients with elevated IOP (24 mmHg 
at least in one eye) showing normal optic disk and normal retinal 
nerve fiber layer. Computerized visual field examinations with 
white-on-white perimetry (Octopus program G1) were normal.
Control Group
This group included eight patients referred by ophthalmologists 
for cataract surgery. Slit-lamp inspection, tonometry, fundoscopy, 
and papillometry were normal in control subjects. In addition, 
nine NHD were included.
Methods
Cardiomyocyte Bioassay—Isolation and Culture  
of Cardiac Myocytes
Primary cultures of cardiac myocytes were prepared from 
ventricle of 1- to 2-day-old Sprague-Dawley rats as described 
previously (37). Briefly, the myocardial cells were dispersed by 
digestion with a 0.25% solution of crude porcine trypsin (Serva, 
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Germany) and were suspended in a SM20-I medium (Biochrom, 
Germany), containing 10% heat-inactivated neonatal calf serum 
(Gibco, Germany), streptomycin (HEFA Pharma; Germany), 
penicillin (Heyl, Germany), hydrocortisone (Merck, Germany), 
glutamine (Serva, Germany), and fluorodeoxyuridine (Serva, 
Germany), the latter to prevent proliferation of non-muscle cells. 
The cardiomyocytes were plated at a field density of 160,000 cells/
cm2. Twenty-four hours after seeding, the culture medium was 
renewed and the cells were cultured for 3–4 days at 37°C before 
stimulation. The medium was replaced with fresh culture solution 
2 h before being used in experiments. Seven to 10 selected cells 
or synchronously contracting cell clusters per flask were counted 
for 15 s on a heated stage of an inverted microscope at 37°C. The 
basal contraction rate of the spontaneously beating cardiomyo-
cytes was measured to be 162 ± 4 min under these conditions. 
If not noted otherwise, the cardiomyocytes were incubated with 
immunoglobulin fractions derived from sera of healthy persons 
and patients for 60 min in a dilution of 1:40. The immunoglobu-
lins were added in excess (in 50 μl: 0.4–0.5 mg IgG fraction; this 
volume was added to 2 ml culture medium/flask). The agonistic 
and antagonistic drugs for the β2AR, peptides, etc. were added 
to the heart cells singly or cumulatively as indicated. β2AR 
activation was induced by the β2AR agonist clenbuterol (Sigma, 
Germany, concentration of 1 µM) and inhibited by the specific 
β2AR blocker ICI118.551 (Sigma, Germany, concentrations of 
0.1–0.3 µM) applied 5 min before. Then, IgG-containing fractions 
of the sera from glaucoma patients were added to cardiomyocytes 
in a standard dilution. The effect of the IgG fractions was antago-
nized by ICI118.551. Performance and in-house validation and 
reproducibility of the bioassay were tested previously (47).
Preparation of the Serum Immunoglobulin Fractions
The immunoglobulin fractions were prepared from sera by direct 
ammonium sulfate precipitation (final concentration of 40%). 
After overnight incubation at 4°C the precipitates were centri-
fuged at 4,000 × g for 30 min, and the pellets were dissolved in 
dialysis buffer (154 mmol/l NaCl, 10 mmol/l Na2HPO4/NaH2PO4, 
pH 7.2). The procedure of precipitating (50% final concentration 
of ammonium sulfate for a removal of small biological active 
compounds such as catecholamines or peptides), washing, and 
dissolving was repeated twice. Prior to the assays all samples were 
extensively dialyzed against phosphate-buffered saline at 4°C for 
3  days. The buffer was changed twice daily. After ammonium 
sulfate precipitation a concentration of 800–900 mg protein per 
milliliter was measured. Fifty microliters of this protein amount 
were inserted for analyses. The immunoglobulin fractions were 
stored at −20°C until use.
affinity Purification of aab
IgG preparations of patients with POAG and OHT were affinity 
purified using the biotinylated peptide biotin-AINCYANETCCD 
corresponding to the second extracellular loop of the β2AR. One 
milliliter of IgG was treated with 300 µl of the peptide (100 µg/ml) 
for 1  h. The peptide–antibody complex was incubated with 
streptavidin-coated magnetic particles (Roche, Germany) for 
30 min. The separation was performed with a magnetic separator 
(Dynal, Germany). The particles were washed five times with PBS. 
The antibodies were eluted with 3 M KSCN in two 0.5 ml steps. 
The antibody solution was dialyzed against PBS for 48 h at 4°C.
Identification of the Target Loop of AAb against β2AR
β2AR-derived peptides identical to the extracellular loops I, II, 
or III were employed to identify the loop that interacts with the 
immunoglobulins isolated from the sera of patients with glau-
coma. The following peptides were selected:
  loop I (HILMKMWTFGNFWCEFWT)
  loop II (HWYRATHQEAINCYANETCCDFFTNQ)
  loop III (VIQDNLIRKEV).
The synthetic loop peptides were added in excess (0.5 µg in 
50 µl) to 50 µl of the immunoglobulin fraction. The mixtures were 
shaken and incubated at room temperature for 1 h. The samples 
were then added to neonatal rat cardiomyocytes cultured in 2 ml 
of medium to a final IgG dilution of 1:40. Sixty minutes after addi-
tion of the peptide/immunoglobulin mixture the beating rate was 
monitored for 15 s.
Epitope Screening on Extracellular Loop II of β2AR
To identify the epitopes of the second extracellular loop of β2AR, 
mapping studies with small overlapping synthetic peptides were 
performed. The interacting sites between specific regions within 
the second extracellular loop and the IgG from glaucoma patients 
were screened with the following peptides:
  HWYRAT (AS172–177),
  ATHQEAI (AS176–182),
  AINCYAN (AS181–187),
  ANETCCD (AS186–192),
  DFFTNQ (AS192–197).
The epitope analysis was performed similar as the loop screening.
IgG Subclass Analysis of the AAb against β2AR
To determine the IgG subclass of glaucoma-associated AAb 
against β2AR, IgGs from selected patients were treated with 
murine monoclonal anti-human IgG1, 2, 3, and 4 antibodies 
(SEROTEC, Germany). According to previous experiments (data 
not shown here), 3 µl of these antibodies were added to 50 µl of 
the IgG preparations. After 1 h at RT the samples were treated 
with 3  µl of a polyclonal anti-mouse Fc antibodies for 1  h to 
increase the complex. The samples were centrifuged at 10,000 × g 
and the supernatants were used in the cardiomyocyte bioassay at 
a dilution of 1:40.
Surface Plasmon Resonance
Binding of the AAb to the β2AR fragments was verified and 
quantified by surface-plasmon-resonance analysis (BIAcore). The 
IgG fractions of patients or controls were passed over biotinylated 
peptides loaded on a streptavidin-biosensor (BIAcore3000) at a 
flow rate of 5  µl/min. As β2AR-derived loop II peptide H19C 
(biotinyl-LC-HWYRATHQEAINCYANETC) was used. A bioti-
nylated unrelated peptide served as control and its sensorgrams 
were subtracted from the specific signals. The initial linear asso-
ciation phase slope under conditions of high density of ligand is 
Table 5 | Pilot proof-of-principal study: demographic data of the four glaucoma patients.
Patient age (years) race sex Diagnosis Perimetric 
mean defect 
before ia (db)
glaucoma history 
(years)
R× before R× in the end
ra la
1 71 Caucasian M OAG 11.7 17.0 12 Dorzolamid 2× none
Timolol 0.5% 2×
Travoprost 1×
2 52 Caucasian F OAG −0.9 0.0 6 Brimonidin 2× Dorzolamid 2×
Timolol 0.5% 2×
Timolol 0.5% 2× Latanoprost 1×
Latanoprost 2×
3 56 Caucasian F OAG 6.8 8.0 5 Dorzolamid 2× Dorzolamid 1×
Timolol 0.5% 2× Timolol 0.5% 1×
4 57 Caucasian M OAG −2.8 0.1 9 Clonidin 4× none
Dorzolamid 2×
Timolol 0.5% 2×
Latanoprost 1×
5
Jünemann et al. AAbs in Glaucoma
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 145
directly correlated with the molar concentration of the binding 
molecules.
Pilot Proof-of-Principal study on ia for the 
Treatment of Patients with POag
In a pilot proof-of-principal study IA was performed in four 
patients with POAG to prospectively study safety and pressure-
reducing efficacy of IA by unspecific removal of IgG and thereby 
the reduction of agonistic AAbs. The study followed the tenets 
of the declaration of Helsinki for research and was approved by 
the local Ethics Committee (3483; ClinicalTrials.gov Identifier 
NCT00494923). All subjects signed an informed consent form 
before participating in any part of the study. Data of a follow-up 
of at least half a year are presented. Levels of AAb and immuno-
globulins as well as IOP were monitored before IA (visit 0: with 
local antiglaucomatous eye drops; visit 1: with systemic antiglau-
comatous medication, yet without local antiglaucomatous eye 
drops), during IA as well as randomly 2 weeks, 2, 4, and 6 months 
after IA. At each visit, the IOP was measured six times a day (7:00 
a.m., 12:00 p.m., 5:00 p.m., 9:00 p.m., 12:00 a.m., 7:00 a.m. of 
the following day). Mean IOP was calculated for each patient for 
statistical analysis.
Patients
The clinical characteristics of the patients are displayed in Table 5. 
All four patients suffered from POAG and were on maximal 
combination therapy with antiglaucomatous eye drops without 
any surgical procedure in the past. Only in the first patient, the 
left eye was excluded from the statistical analysis since he had 
undergone trabeculectomy in the past. Inclusion criteria were the 
failure of the current therapy to control IOP and the refusal of 
surgical procedures. Two female and two male Caucasian patients 
aged between 52 and 71 years were included. Systemic diseases of 
the patients were:
  patient 1 nephrectomy because of cancer in 1995,
  patient 2 arterial hypertension,
patient 3 asthma bronchiale, hyperthyreosis,
patient 4 spine arthrosis, cyste of the hip, tinnitus.
Immunoadsorption
All four patients underwent one treatment cycle of five con-
secutive days from Monday to Friday. Two Globaffin® adsorbers 
(double-columns system, columns for re-use; Fresenius Medical 
Care Affina GmbH) were used (48). Each adsorber contains 60 ml 
of a matrix based on sepharose CL-4B, suspended in sodium 
citrate buffer (10 mM; pH 4.0). One adsorber contains at least 
250  mg of PGAM146 peptide covalently bound to Sepharose. 
The full synthetic peptide PGAM146 is a ligand for IgGs and 
binds them independent of the antigen specificity. The synthetic 
peptide PGAM-146 mimics a protein A ligand. In Globaffin the 
peptide is used as ligand to bind immunoglobulins from human 
plasma. The high affinity to all immunoglobulins (esp. IgG) or 
immunocomplexes that contain this Fc-part makes the peptide to 
a potential ligand for the removal of these substances. The peptide 
ligand is immobilized to cross linked agarose (Sepharose CL-4B). 
During treatment, the columns were regenerated with special 
buffer solutions (15  g/l glycine-hydrochloric acid, pH 2.8 and 
8 g/l NaCl, 0.2 g/l KCL, 3.6 g/l Na2HPO4 × 12 H2O (phosphate-
buffered saline, PBS) solution). After termination of the treatment, 
the Globaffin® adsorbers were preserved using bacteriostatic and 
toxic buffers [0.4  g/l polyhexamethylene-biguanide (PHMB), 
0.3 g/l tryptophan, 3.3 g/l sodium citrate dihydrate, 5.4 g/l sodium 
acetate trihydrate, 2.9 g/l sodium monohydrogen phosphate × 12 
H20, 0.26 g/l potassium dihydrogen phosphate, pH 7.0 (PHMB-
Trp) solution]. For preservation, each adsorber was rinsed with 
at least 350 ml of preservation buffer [0.1 g/l sodium azide (PBS, 
0.1%)]. Afterward, the adsorbers were stored at 2–10°C until 
the next treatment cycle. Extracorporal plasma separation was 
performed by centrifugation (Cobe Spectra®) while the running 
parameters, such as column volume, loading volume (250  ml/
cycle), desorption and regeneration volume, speed of processing, 
and numbers of cycles, were fixed and controlled by the Adasorb® 
device (medicap, Ulrichstein). Prior to connecting the patient 
FigUre 2 | β2-adrenergic receptor (β2AR) agonistic autoantibodies (AAbs) in 
patients with primary open-angle glaucoma (POAG) or ocular hypertension 
(OHT). The neonatal cardiomyocytes were incubated with the immunoglobulin 
fractions from POAG (n = 33) and OHT (n = 14) patients as described in 
Figure 1. The agonistic effect of the AAbs was blocked by the β2AR 
antagonist ICI118551 (ICI; 0.1 µM). ICI (0.1 µM) did not affect the basal 
beating rate of the cardiomyocytes.
FigUre 1 | Antibodies stimulating rat cardiomyocytes in sera of patients with 
POAG and OHT. Immunoglobulin-enriched serum fractions were added to 
cardiomyocyte cultures in a 1:20 dilution and incubated for 60 min at 37°C. 
The data are displayed as the changes of the beats/min. Each point 
represents 6–10 separate single-cell check points in a culture flask. Repeated 
measurements of the effects with different cell cultures prepared on different 
days resulted in almost identical data. The differences between patients with 
POAG or OHT versus healthy controls were highly significant. Primary 
open-angle glaucoma (POAG, n = 37); ocular hypertension (OHT, n = 9); 
cataract (n = 10); healthy donors (NHD, n = 10).
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to the system, the adsorber was washed with 2  l of 0.9% NaCl 
solution. During treatment, the plasma was alternately passed 
through the adsorbers. One adsorber served for the removal of 
immunoglobulins, the second was simultaneously regenerated 
by a glycin buffer. The amount of plasma to be treated (plasma 
volume, PV) was calculated before the treatment [females: PV 
(ml) = a × 9.03 + b × 24.13 − 766; males: PV (ml) = a × 19.9 + 
b × 13.1 − 2,000 (a = body height in cm; b = body weight in kg)].
Procedure of IA
Before the procedure, a 1250 IE heparin i.v. bolus was given. 
Access to circulation was provided via the cubital vein. Peripheral 
blood was drawn, anti-coagulated, and separated into plasma 
and blood cells. Extracorporal anti-coagulation was achieved by 
sodium citrate (ACD-A, 2.2%; 1:15–1:20 v/v to blood). The plasma 
was pumped through an adsorber column (Globaffin®) regulated by 
the Adasorb® device. The separated plasma was perfused through 
the columns at a flow rate between 11 and 28 ml/min; one cycle 
contained 250 ml plasma. The treated plasma was subsequently 
remixed with the other blood components and reinfused. During 
one cycle of treatment, the twofold volume of the individually 
calculated plasma volume was cleared by the adsorber.
statistical analysis
Student’s t-test was used to compare variables between the 
groups. Values of P < 0.05 are significant. Continuous data are 
presented as medians (with ranges). We performed comparisons 
between groups with use of Fisher’s exact test for categorical 
values and the Mann–Whitney U test for continuous variables. 
In addition, statistical analysis was done using four-field analysis.
resUlTs
sera of Patients with POag and OhT 
contain aab stimulating rat 
cardiomyocytes
Immunoglobulin-enriched fractions of sera of patients with 
POAG, OHT, cataract, and of healthy donors (NHD) were 
analyzed for AAbs against GPCRs. We calculated the cutoff as 
mean of the beating rate in normals added to three times of the 
SD. As shown in Figure 1, the beat rate of cardiomyocytes was 
increased by the immunoglobulin fractions in POAG, OHT, yet 
not in cataract and NHD. 73% of the POAG patients and 78% of 
the OHT patients showed increased beat rates of the cardiomyo-
cytes, whereas 0% of the cataract and NHD yielded an increased 
beat rate. This indicates the presence of agonistic AAb in patients 
with POAG and OHT. To identify the specific target(s) and IgG 
fraction of these AAb receptor-specific analyses were performed.
immunoglobulins from POag and OhT 
Patients Interact with the β2ar
The positive chronotropic responses of the AAb from patients 
with POAG and OHT were analyzed for their receptor specificity 
using respective antagonists. The action of AAb on the cardio-
myocytes was blunted by ICI118.551 and the β1/β2 adrenergic 
antagonist propranolol (Figure 2), but not by bisoprolol (β1AR 
antagonist) or losartan (AT1 antagonist; not shown). The β2AR-
specific agonist clenbuterol enhanced the cardiomyocyte beat rate 
of all samples, indicating functionality of the detection system 
(not shown).
FigUre 3 | Time response curve of β2 adrenergic agonists. Effect of (a) the agonistic autoantibody (AAb) prepared from patients with primary open-angle 
glaucoma (POAG) or ocular hypertension (OHT) on spontaneously beating rat cardiomyocytes and (b) clenbuterol (Clen). Clenbuterol induced a desensitization of 
the β adrenergic response within 2 h. After 2 h, clenbuterol was washed out and restimulation with clenbuterol resulted in approximately 30% of the initial stimulation 
(b). β2-adrenergic receptor AAb showed no desensitization for at least 5 h (a). Before washing, the antibodies were removed from the receptors by ICI118551. 
After washing, the cells react to a clenbuterol stimulation with a maximal response (n = 10 for each point of measurement).
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Reportedly, agonistic AAb against the β1 adrenoceptor or 
monoclonal antibodies against the second extracellular loop 
of the β2 adrenoceptor did not desensitize the corresponding 
receptors within 4 to 6 h (49). Therefore, we analyzed the long 
term effect of the β2 AAb prepared from patients with POAG. 
The AAb did not induce desensitization of the β2AR within 5 h. 
ICI118.551 normalized the beating rate of the cardiomyocytes. 
A successive washing procedure removed ICI118.551 and the 
AAbs. When the washed cells were stimulated with the β2 agonist 
clenbuterol, a maximal response to this agonist was to be observed 
(Figure  3A). On the other hand, clenbuterol desensitized the 
receptor mediated signal cascade and decreased the beating 
rate of the cardiomyocytes. After washing out the agonist and 
a further stimulation with clenbuterol, we observed an increase 
of the beating rate by only 30% of the response obtained in the 
first stimulation with clenbuterol. We conclude that, in contrast 
to clenbuterol (Figure 3B), AAb did not desensitized the β2AR 
mediated signal cascade.
The β2 aab recognize Two Peptide 
epitopes of the second extracellular  
loop ii of the β2ar
The binding of the AAb to distinct extracellular loops of β2AR 
was characterized in the presence of loop-specific synthetic 
peptides. As presented in Figure  4 only the loop II peptide 
neutralized the agonistic activity. This indicates that the second 
extracellular loop of β2AR is the target of the AAb in the sera of 
patients with glaucoma.
To identify the epitopes of the AAbs, we pretreated the AAb 
with short overlapping peptides corresponding to the second 
extracellular loop of the β2AR. For these studies five synthetic 
Table 6 | Surface plasmon resonance analysis of binding of IgG fractions to the 
biotinylated H19C peptide (biotinyl-LC-HWYRATHQEAINCYANETC) derived from 
loop II of the β2AR.
Proband initial association phase slope on h19c peptide
1 0.441
2 0.0579
3 −2.98E−03
4 0.102
5 0.0439
6 0.0572
7 −0.0544
8 0.333
9 −0.0224
10 0.0955
11 0.102
12 0.176
13 0.413
14 0.326
15 0.11
16 0.396
17 0.115
18 0.356
FigUre 5 | The agonistic anti-β2AR autoantibodies (AAbs) of patients with 
primary open-angle glaucoma (POAG) recognize the epitopes AINCYAN and 
ANETCCD of loop II. The procedure to detect epitope-specific responses of 
immunoglobulins isolated from POAG patients is similar to the one used in the 
studies for loop analyses. The final AAb dilution was 1:40. Data are displayed 
as individual measurements of five independent patients with POAG.
FigUre 4 | The agonistic anti-β2AR autoantibodies (AAbs) of patients with 
primary open-angle glaucoma (POAG) recognized the second extracellular 
loop of the β2-adrenergic receptor. The antibody preparations from patients 
with POAG (n = 5) were pretreated with loop-specific peptides corresponding 
to the extracellular loops I–III. The antibody–peptide complexes were added 
to the cardiomyocytes to measure remaining agonistic capabilities. The final 
AAb dilution was 1:40. The data are presented as the increase in beats/min 
versus baseline beating rates.
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oligopeptides were prepared covering the loop II amino acid 
172–197. Only the loop II-borne peptides AINCYAN (181–187) 
and ANETCCD (186–192) abolished the agonistic activity of the 
AAb from five representative patients with POAG (Figure 5) and, 
thus, represent the dominant epitope of the β2AR.
affinity Purified aab of POag and OhT 
Patients induce agonistic effects in a 
Dose-Dependent Manner
Affinity purified AAb against the β2AR exert a dose-dependent 
positive chronotropic effect on cultured spontaneously beating 
rat cardiomyocytes. The maximal response for the POAG and 
OHT was observed at a dilution of the antibodies of 1:200 and 
1:100, respectively.
surface Plasmon resonance analysis 
confirmed the receptor specificity  
of the agonistic aab
Surface plasmon resonance allows to determine direct physico-
chemical interactions between macromolecules. Analyzing the 
IgG fractions of sera from patients with glaucoma we observed 
a significant binding activity to a loop II peptide from the β2AR 
(Table  6). We subjected the values to a statistical four-field 
analysis. The Fisher-test revealed a significance of p = 0.01282, 
a relative risk (CI) of 0.37721 (0.37093–0.84993), a sensitivity of 
0.35 and a specificity of 0.0066. Therefore, the AAb from the sera 
of patients with glaucoma display a higher affinity for the loop II 
of the β2AR than those of controls.
The Agonistic β2ar aab in the Sera of 
Patients with POag are of the igg3 
Isotype
To define the nature of the molecules in immunoglobulin-
enriched fractions, which increased beating rates of cardio-
myocytes, we used antibodies against immunoglobulins IgG and 
IgM (Figure 6). Only anti-IgG significantly prevented the ago-
nistic activity. We next analyzed the IgG subclass of the agonist- 
like β2AR AAb with antibodies specifically depleting certain 
IgG subclasses (Figure  7). Only IgG3-precipitating antibodies 
eliminated the agonistic activity. Therefore, most of the agonistic 
AAb are of the IgG3 isotype.
clinical Parameters in correlation to aabs
We analyzed the clinical parameters of the patients with respect 
to treatment for glaucoma, IOP, and general diseases including 
FigUre 6 | Agonistic anti-β2AR IgG autoantibodies in patients with primary 
open-angle glaucoma. The neutralization of IgG from the immunoglobulin-
enriched fraction lead to the loss of the stimulatory potential. Antibodies 
against IgM had no effect. The β2 receptor agonist clenbuterol served as 
positive control (not shown).
FigUre 7 | IgG3 subclass of the agonistic anti-β2-adrenergic receptor 
autoantibodies in patients with primary open-angle glaucoma. The 
neutralization of IgG3 from the immunoglobulin-enriched fraction leads to the 
loss of the stimulatory potential. Antibodies against IgG1, 2, and 4 had no 
effect. The β2 receptor agonist clenbuterol served as positive control (not 
shown).
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cardiovascular disease and diabetes (Tables 3 and 4). We could 
not detect any correlation of these parameters between AAb 
positive POAG and OHT patients with NHD or AAb negative 
patients (data not shown).
Pilot Proof-of-Principal study on ia for 
Patients with POag
The IA was well tolerated in all patients—no adverse events were 
to be observed. Specifically, no change in visual acuity, visual 
field, and intraocular flare measured by laser flare cell meter was 
detected (not shown). The levels of the AAb before and after IA 
are shown in Table 7. The IOP course is presented in Table 8 for 
each patient. Time course of IOP and levels of AAbs during IA 
are shown in Figure 8.
The individual IOP course of each patient was as follows.
Patient 1 (Male, 71 Years Old)
Mean IOP before immune adsorption of the first patient showed 
a reduction only during the first days of IA (Figure 8A. The IOP 
dropped from 15.6 ± 1.8 mmHg to 15.1 ± 03 mmHg (3.2%) dur-
ing the first day and raised to 23.9 ± 1.9 mmHg during the last day 
of IA. Because of the advanced stage of glaucoma, trabeculectomy 
was performed 4 weeks after IA.
Patient 2 (Female, 52 Years Old)
In the second patient largest reduction of IOP was found 2 months 
after IA (visit 4) (Figure 8B). IOP dropped about 27.8% at the 
right eye (OD) and 32.1% at the left eye (OS) if compared to 
IOP at visit 1. At visit 7 (12 months after IA) mean IOP was still 
decreased by about 21.9% at the right eye and 12.5% at the left eye 
in comparison to visit 1.
Patient 3 (Female, 56 Years Old)
Largest drop of IOP was found in the third patient (Figure 8C). At 
visit 4, the reduction of IOP was 11% for the right eye and 46.3% 
for the left eye with additional two topical medications. Without 
topical medications, IOP reduction was found to be 12.5% at the 
left eye, yet IOP increase of about 11% at the right eye (visit 2, 
2 weeks after IA) compared to IOP at visit 1.
Patient 4 (Male, 57 Years Old)
The fourth patient showed the lowest IOP measurement (without 
topical medication) at the end of the observation period (without 
medication visit 7) (Figure 8D). One month after IA, IOP was 
equal to IOP before IA (without medication, visit 1) with an 
increase of mean IOP up to 23.5 ± 4.6 mmHg at the right eye and 
23.5 ± 4.0 mmHg at the left eye (6 months after IA, visit 6). In 
comparison to visit 0 (three medications), no topical medication 
was necessary at the end of the observation period.
Taking together, in all patients, AAb and other IgGs were 
washed out almost completely by IA, resulting in autoantibody 
concentrations below the detection limit at the end of treatment. 
In two patients (1 and 3) AAb remained undetectable during 
the 6 months follow-up period. The two other patients showed 
detectable AAb-levels 4 months after IA. The reduction of total 
IgG and IgG3 levels ranged from 88 to 95 and from 64 to 80%, 
respectively. Four weeks after IA total IgG and IgG3 concentra-
tions reached normal values.
DiscUssiOn
In the present study, we describe formerly unknown circulating 
AAb in patients with glaucoma (50). We screened patient sera 
for antibodies that activate a GPCR expressed by cardiomyocytes 
and detected AAb against the β2AR employing specific inhibitory 
peptides. These agonistic AAb induced a dose-dependent stimu-
lation and their effects were blocked by the selective antagonist 
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Table 7 | AABs, IgG (mg/dl), and IgG3 (mg/dl) before and after immunoadsorption (IA).
before ia end of ia after ia
2 weeks 2 months 4 months 6 months
1 AAB 5.8 0 −0.25 −0.25 −0.38
IgG 1,190 134 469 859 1,000
IgG3 51.8 16.3 32.5 38.1 42.2
Date of examination (25.09) (29.09.) (06.10) (09.11) (16.05 of following year)
2 AAB 4.63 0.75 0 −0.88 6.0 7.67
IgG 1,500 122 1520 1,410
IgG3 44.8 15.1 37.1 47.6
Date of examination (13.11) (17.11) (07.02 of following year) (22.06 of following year)
3 AAB 7.25 0.67 0.33
IgG 1,370 178 574 914 1240
IgG3 49.1 17.9 31.8 59.1
Date of examination (07.05) (11.05) (25.05) (20.06) (21.08)
4 AAB 3.83 −0.17 3.17
IgG 1,150 92.0 773 1030 1,020
IgG3 54.2 15.9 61.4 91.3
Date of examination (04.08.) (08.08) (25.08) (14.10) (17.02 of following year)
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ICI118.551, and neutralized by peptides corresponding to the 
second extracellular loop of the β2AR (AS 181–192).
Autoantibody can be detected by several methods: (1) enzyme-
linked immunosorbent assay detects the patient’s antigen bound 
AAb by a specific (to human IgG) animal sourced and enzyme 
(peroxidase or alkalic phosphatase) labeled antibody; (2) fluo-
rescence (microscopy) detects AAb as (1), but the detection of 
the AAb is fluorescence labeled (e.g., fluorescein isothiocyanate, 
FITC); (3) radioimmunoassay detects AAb as (1), however, the 
detection of the AAb is radio labeled (e.g., iodine); (4) bioas-
say (with spontaneous beating neonatal rat cardiomyocytes) 
measures the increase in the beating rate, induced by added IgG 
(fraction from human serum) due to the binding of AAb to the 
corresponding receptor (here: β2-AR). The detection methods 
(1)–(4) measure the AAb indirectly, however method (4) addi-
tionally directly. As the detected signal extent of the bioassay is 
proportional to the AAb bound to the surface fixed target, we 
decided to choose the cardiomyocyte bioassay for the detection 
of the AAb. Next to the detection of the AAbs, this method 
enables functional analyses.
The AAb found in glaucoma patients are of the IgG3 subclass. 
The antibodies that trigger effector functions, and that are most 
likely to be involved in immunoregulatory activity, are IgG3 
and IgG1 (51). In addition, it is known that IgG3 is involved 
in antibody-dependent cellular cytotoxicity (52). Complement 
activation is most effective with IgG3 and, to a lesser extent, 
with IgG1, IgG2, and IgG4. Usually, complement binding and 
activation leads to destruction of the target structure. The plasma 
concentration of IgG3 is low, and its half-life is shorter than that 
of any of the other IgG-subclasses. Further investigations are 
necessary to elucidate whether complement activation and cell 
death are involved in the pathogenesis of glaucomatous diseases.
Recent studies support the hypothesis that glaucoma-
associated neurodegenerative processes are partially caused by 
immune-mediated mechanisms (53–56). These studies report 
complex AAb repertoires in patients with glaucoma which were 
directed against retinal and optical nerve antigens. Such autoan-
tibody reactivities were shown in optical nerve extracts from 
bovine eyes. The later findings are of interest in respect to ocular 
pressure-dependent and independent autoimmune responses. 
With regard to AAb-mediated immunoreactions, these patho-
mechanisms seem to be driven by inflammation.
The β2AR is one of the best investigated GPCR. The modula-
tion of cardiac contractility is also mediated by β2AR, and its 
activation might have chronic effects on cellular metabolism, 
on cell growth, or on excitability (57). This receptor seems to 
be involved in allergic asthma, several cardiomyopathies, such 
as Chagas’ disease, and cardiac electrical disturbances (58–60). 
However, whereas the AAb in the case of Chagas disease were 
functionally active in cardiomyocytes, β2-AAb from asthmatic 
patients react in the opposite way. Respective loop analyses 
explained these findings; in the Chagas-related cardiac disorders 
the loop II was identified to be the target of AAbs, whereas in 
the asthmatic disease the loop III was recognized. Thus, it was 
concluded that the various extracellular loops of the β-AR are 
functionally linked to distinct antibody-mediated responses.
Several years ago, the effect of monoclonal antibodies directed 
against the second extracellular loop of the beta2 adrenoceptor 
was investigated. Interestingly, similar results were detected as 
seen with the AAbs prepared from the sera of glaucoma patients 
(61). The agonist-like effect of this mAB (6H8) was blocked by 
the specific β2-adrenergic antagonist ICI118.551 and a peptide 
HWYRATHQEAINCYANETC corresponding to the second 
extracellular loop of the β2-adrenoceptor. The β1-adrenoceptor 
antagonist bisoprolol was without influence. The AAb were 
directed against loop II and recognized the overlapping epitopes 
AINCYAN and ANETCCD. Considering that the peptide 
corresponding to the second extracellular loop and the short 
overlapping peptides cannot form the correct conformation 
of the extracellular loop, the anti-β2 receptor antibodies were 
pretreated with the peptides corresponding to the first, second 
or third extracellular loop for 1 h. Under these conditions, only 
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the peptide that corresponds to the second extracellular loop was 
able to neutralize the AAb activity. The peptides of the first and 
third extracellular loops were without effect. Similar results we 
observed also for the short overlapping peptides with an amino 
acid sequence of 5–6 amino acids. In these experiments, the 
sequence (AINCYANETCCD) was able to neutralize the AAb 
action. Therefore, it is assumed that this sequence represents the 
epitope of the AAb on the second extracellular loop. Plasmon 
resonance and affinity purification confirmed the direct interac-
tion of the AAb with loop II of the β2AR. The agonistic β2AR 
antibodies described here are good mechanistic candidates that 
might induce and maintain an elevated IOP as a critical step in 
the development of glaucomatous diseases.
In this study, we present first in vivo data of four patients with 
POAG that underwent IA in a pilot proof-of- principal study: 
glaucoma therapy is considered to be effective when IOP reduc-
tion is 20% from wash out baseline (62). Even not all patients 
in a study group must show a substantial IOP decrease of 20%, 
in cases when representative parts of the patients display even 
more than 20% IOP reduction. Thus, an IOP decrease could be 
observed in 3 of 4 patients after IA: patients 2 and 3 showed an 
IOP decrease of 27.8% (OD)/32.1% (OS) and 11% (OD)/46.3% 
(OS) using equal number of topical antiglaucomatous eye 
drops. An IOP decrease of 2.9% (OD) and 6.2% (OS) could be 
observed 12 months after IA in patient 4. As it is known that each 
single millimeter of mercury increases glaucoma progression 
rate about 12–13% (18) even the IOP decrease in this patient 
is important and enables winning sighted lifetime. The IOP of 
patient 4 is considered to be even lower after IA as the number 
of local antiglaucomatous eye drops decreased from 4 to 0, thus, 
measured IOP values under no local therapy can be seen as a 
lowered IOP after IA with even higher IOP under quadruple 
therapy before IA. Summarizing, immunoadsorption seemed 
to lower IOP or even number of antiglaucomatous therapy. 
Possibly, the decrease of IOP could even be larger, if β2AR AAbs 
are blocked specifically. Because IA is a non-specific method 
for adsorbing AAbs and other IgGs, several other AAb were 
removed in addition to the agonistic β2AR AAb. As known for 
other autoimmune diseases, AAb relapse. This effect was also 
seen in our patients. Detection of β2AR AAbs went along with 
an IOP increase (patients 2 and 4). The delay in the decrease of 
IOP might be possibly due to a re-sensitization of the β2AR in 
the absence of stimulating AAbs. In addition, the therapy was 
well tolerated and no adverse effects were observed.
The most important target of glaucoma treatment is elevated 
IOP. A large body of evidence has established the importance of 
the reduction of the IOP in the medical management of glauco-
matous diseases (13–17, 63). The pathogenic damage of the optic 
nerve in POAG is not well understood. It is supposed to be asso-
ciated with increased IOP, glutamate toxicity (64), interrupted 
transport of neutrophins (8), apoptosis (4, 65), extracellular 
matrix changes (5, 6), and hypoxia due to ocular and systemic 
vascular dysregulation (66).
The aqueous humor dynamic plays the major role in the regu-
lation of IOP. Four factors maintain the steady-state IOP of the 
healthy eye. These are flow of aqueous humor, resistance to out-
flow, episcleral venous pressure (67), and uveoscleral outflow (68). 
FigUre 8 | Continued
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FigUre 8 | Time course of IOP, levels of autoantibodies (AAbs) and number of local antiglaucomatous eye drops during immunoadsorption (IA) for the patient with 
primary open-angle glaucoma (POAG). Patient 1/2/3/4 (A)/(B)/(C)/(D): a decrease in IOP under reduced number of local antiglaucomatous therapy was to be 
observed in all patients, going along with a decrease of the AAb. Intraocular pressure (IOP) increased, when AAbs relapsed after the IA; OD, right eye (black); OS, 
left eye (red); grayish area, data before IA; visit 1, IOP graph: less than 3 months before immunoadsorption under maximal combination therapy, AAB against β2AR 
graphs: before immunoadsorption; visit 2 – IOP graph: two days before immunoadsorption with system medications (acetazolamide), yet without topical 
medications, AAB against β2AR graphs: at the end of immunoadsorption; IOP/AAB against β2AR graphs: visit 3–2 weeks after immunoadsorption; visit 4–1 month 
after immunoadsorption; visit 5–2 months after immunoadsorption; visit 6–4 months after immunoadsorption; visit 7–6 months after immunoadsorption; visit 
8–12 months after immunoadsorption.
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The IOP reflects the balance between in- and outflow of aque-
ous humor. A major strategy in medical treatment of glaucoma 
is the reduction of inflow and, thereby, normalization of IOP. 
Understanding the mechanisms and regulation of inflow is, thus, 
of undoubted clinical relevance. Several mechanisms underlying 
increased inflow have been identified, however, the integration 
and regulation of these mechanisms is still elusive (69). The 
balance of in- and outflow of aqueous humor is modulated by 
the local β2AR activity and may be chronically influenced by 
agonistic AAbs.
Usually, night-time aqueous flows are approximately half of 
those observed at daytime in active humans (70–72). The ability 
of aqueous flow stimulation by epinephrine during night-time 
shows a low basal β-adrenergic stimulation during the night 
(23). Patients with POAG form in average 15% more aqueous 
humor/24 h than control subjects of the same age. This is due to 
a significantly higher aqueous flow in the night in comparison to 
control subjects (73). Thus, a β-adrenergic overdrive precludes 
the downregulation of the aqueous flow during the night. This 
observation is underlined by the lack of receptor desensitization 
by agonistic AAb displayed in Figure 3. Usually, β2AR agonists 
such as clenbuterol desensitize the receptor within 1–2  h 
(Figure 3B). By contrast, the β2AR AAb do not desensitize the 
β2AR in vitro for at least 5 h. This chronic β2-adrenergic stimula-
tion may explain the higher aqueous flow and the elevation of the 
IOP in patients with POAG. Alteration of the circadian rhythm 
of IOP in POAG can be explained by the presence of AAb. The 
lack of tachyphylaxia was also observed for agonistic antibodies 
against anti-β1AR-, anti-α1AR-, anti-AT1-, and anti-muscarinic 
M2 receptor in several cardiovascular diseases (74, 75).
The AAb might also play a modulatory role in the aqueous 
outflow. Putney et  al. (76) found an increase of cell volume of 
trabecular meshwork cells via Na+-K+-Cl− cotransporters in glau-
coma leading to a reduced outflow. As β-adrenergic stimulation 
results in an activation of Na+-K+-Cl− cotransporters, agonistic 
AAb might also contribute to reduced outflow facility.
An “organ specificity” for the AAb against the β2AR can be 
assumed as patients of glaucoma suffered not of other diseases, 
which can be caused by these AAb (e.g., allergic asthma). It 
can be hypothesized that the chemical surrounding has to be 
changed before the autoantibodies can act specifically. Previous 
data showed that the βAR is not accessible for the AAb under 
adequate oxygen conditions. However, the βAR seemed to be 
unmasked, if ischemia occurred (77, 78). This could be a poten-
tial reason as glaucoma is hypothesized to be a disorder with 
local ischemia (79).
The data presented here offer another insight into eye disorders 
associated with high IOP. The newly identified AAb against the 
β2AR were exclusively found in the sera of patients with POAG 
and OHT but neither in those with cataract, nor in controls. 
Based on these observations, we suggest that these AAbs are not 
only immunological markers with a high incidence in POAG 
and OHT, but might also be pathomechanistically relevant β2AR 
activating molecules. The common, broadly successful therapy 
with β2AR antagonists further supports the idea that AAb-
mediated mechanisms might be of pathogenic importance. In 
addition to their effect on IOP, the AAb might also have a direct 
effect on retinal ganglion cells as β-adrenoreceptor antagonists 
showed neuroprotective properties (80).
cOnclUsiOn
In patients with POAG and OHT, however, not in controls, ago-
nistic AAb directed to β2AR were detected. These AAb interacted 
with the second extracellular loop of β2AR (peptides 181–187 and 
186–192), thus functionally different links to distinct antibody-
mediated responses are assumed. Data of our clinical pilot proof-
of-principal study might suggest that a reduction of total IgG, 
including AABs against β2AR (IgG3 isotype) by IA, transiently 
decreases IOP. These findings might indicate a possible role of 
these AAb in the dynamics of aqueous humor and might support 
a contribution of adaptive autoimmunity in the etiopathogenesis 
of POAG and OHT. A specific blocking of AABs against β2AR 
might be of interest for further studies.
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